| SC 13G/A | 2024-02-09 | GOLDMAN SACHS GROUP INC | LUMOS PHARMA, INC. | 406,711 | 5.1% | EDGAR |
| SC 13G | 2024-02-06 | WELLS FARGO & COMPANY/MN | LUMOS PHARMA, INC. | 417,051 | 5.3% | EDGAR |
| SC 13D/A | 2023-11-29 | Blackstone Holdings II L.P. | LUMOS PHARMA, INC. | 385,683 | 4.9% | EDGAR |
| SC 13D/A | 2023-06-20 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 400,000 | 4.9% | EDGAR |
| SC 13D/A | 2023-06-02 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 496,891 | 6.1% | EDGAR |
| SC 13D/A | 2023-05-25 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 643,338 | 7.9% | EDGAR |
| SC 13D | 2023-02-15 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 760,000 | 9.1% | EDGAR |
| SC 13G | 2023-02-07 | GOLDMAN SACHS GROUP INC | LUMOS PHARMA, INC. | 469,402 | 5.6% | EDGAR |
| SC 13G/A | 2023-01-24 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 760,000 | 9.1% | EDGAR |
| SC 13G/A | 2022-02-02 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 496,811 | 5.9% | EDGAR |
| SC 13G | 2022-02-01 | Farb Daniel Stuart | LUMOS PHARMA, INC. | 496,811 | 5.9% | EDGAR |
| SC 13D/A | 2022-01-05 | New Enterprise Associates 14, L.P. | LUMOS PHARMA, INC. | - | - | EDGAR |
| SC 13D | 2021-08-30 | SHV Management Services II, LP | LUMOS PHARMA, INC. | 676,832 | 8.1% | EDGAR |
| SC 13G/A | 2021-05-26 | Flynn James E | LUMOS PHARMA, INC. | 161,714 | 1.9% | EDGAR |
| SC 13G/A | 2021-02-12 | Lion Point Capital, LP | LUMOS PHARMA, INC. | 407,192 | 4.9% | EDGAR |
| SC 13G/A | 2021-02-12 | Flynn James E | LUMOS PHARMA, INC. | 936,291 | 11.3% | EDGAR |
| SC 13G/A | 2021-02-11 | RENAISSANCE TECHNOLOGIES LLC | LUMOS PHARMA, INC. | 308,812 | 3.7% | EDGAR |
| SC 13D | 2020-04-01 | New Enterprise Associates 14, L.P. | LUMOS PHARMA, INC. | 524,030 | 6.3% | EDGAR |
| SC 13D | 2020-03-30 | Blackstone Holdings II L.P. | LUMOS PHARMA, INC. | 468,145 | 5.6% | EDGAR |
| SC 13G/A | 2020-02-18 | Link Charles J. Jr. | NEWLINK GENETICS CORP | 690,531 | 1.8% | EDGAR |